Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot
about
Canagliflozin: A Review in Type 2 Diabetes.The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UKUpdates on cardiovascular outcome trials in diabetes.Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).Can we go beyond surrogates?Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes.The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4.Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world.Canagliflozin and cardiovascular and renal events in type 2 diabetes.The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016).Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus.Pharmacological management of type 2 diabetes: what's new in 2017?Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study.Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness.Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.10th Annual Symposium on Self-Monitoring of Blood Glucose, April 27-29, 2017, Warsaw, Poland.Managing diabetes patients in India: Is the future more bitter or less sweet?Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.Cardiovascular outcomes with canagliflozin - is it on the CANVAS?Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review.Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real WNon-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.Empagliflozin across the stages of diabetic heart disease.Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.The year in cardiology 2017: prevention.Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.
P2860
Q40081685-8C446598-7410-4C13-8D6E-3E91AFF80A4EQ40106543-FDEB52FF-5C6D-4215-B9BB-8B64BB105FD5Q41176211-90FDA083-125C-4FBC-869A-6679F5BC26F1Q42371759-FB90993E-E5D1-4057-9DEC-53D447D9125EQ42375211-9A6F16BB-5D8D-4282-A345-6ED5AF038645Q42376648-2534F793-932A-4646-BD1B-DC9271633A35Q42643753-C0999265-AA14-4CB4-A7DF-155FF962C090Q46523978-601C7C0E-3A4C-40ED-9F75-AB8058BBB78CQ47109331-1B922F9A-739C-4760-84A5-E25CD9BBE016Q47110037-4AD226D1-5E42-47BB-8858-E3DF8D93BEEAQ47149127-C3EE813D-D5D0-4898-9A76-E9D67284C14EQ47154265-3F91B2B2-DEAA-4CFA-9D41-6FD6633B91ECQ47215015-C7FEE4BE-B4A5-47BF-85E5-BD93F6EFA4E0Q47261527-2EE82DE7-6134-404D-BC09-0750638DC455Q47297477-8C028F7E-7A29-4649-B7B3-361CE07E1BB7Q47614541-7D246535-8D0D-4338-AA8A-2220BA7F2003Q47652080-421734E4-5746-4315-9A56-AA2473CC3A70Q47665909-86EC7A3B-16C0-4279-ACA2-5DFC1E8999B5Q47672213-63ECF7C2-EBBF-4452-84A0-0F9F5142B53EQ47696671-0633B2A3-2E3B-4B85-9098-6488212A5149Q47871089-C9F4BF01-2230-4995-A5FC-BB1DCB1F850CQ48114481-1C7B674A-ACBE-4DA2-A426-88AEE4EBD36AQ48228143-BC325C30-95A1-45B0-8106-95BFC3DB4062Q48296619-B2CDAA33-E6C1-40F1-A7DA-3B5D4A266B15Q48363461-CC4A1BB7-A6D3-4862-A3DD-0ED00A132511Q48556396-CB1AD258-63C9-48A6-A258-4E1F3F1BF216Q49443583-4EF9E282-DBAF-4342-8AFD-51BF654EE621Q49473968-D8A8E57D-4384-44BB-95CC-0DB2592B5D42Q49691150-418C48C1-6137-4114-BC71-581881F95367Q49843638-E1C1D3F3-C6BB-4BAC-87F6-C53B89392925Q50026688-0FD325AF-EB64-4366-A6CC-DD9C48ECEFCCQ50042476-EA6E9BA8-DCB0-4AB5-9C80-6009740ED712Q50067957-B0EDF4C8-E603-49C6-B961-6CD0EECE0C07Q50094178-B162E621-7AB4-46EE-ADAB-8468E26399B5Q50145776-EF0A555F-FDFD-47C1-A08A-4DF43B6DB1BFQ50145783-83205C48-4947-45AE-A6BD-6915442FE14FQ50193445-AB09AF36-16B3-47B2-A5FD-EAB13C58C980Q51764933-71C90AC4-20EA-4D2A-A279-B733A16AF82DQ52562709-5C279647-0F11-4B6E-889C-D5CA6A416EB9Q52673331-DAD73FD7-A430-4AEA-BD73-239612F3AEF1
P2860
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Lower Risk of Heart Failure an ...... ew Users of Sodium-Glucose Cot
@en
type
label
Lower Risk of Heart Failure an ...... ew Users of Sodium-Glucose Cot
@en
prefLabel
Lower Risk of Heart Failure an ...... ew Users of Sodium-Glucose Cot
@en
P2093
P2860
P50
P921
P1433
P1476
Lower Risk of Heart Failure an ...... ew Users of Sodium-Glucose Cot
@en
P2093
CVD-REAL Investigators and Study Group*
Johan Bodegård
Kamlesh Khunti
Kåre I Birkeland
Matthew A Cavender
Mikhail Kosiborod
Niklas Hammar
Peter Fenici
P2860
P304
P356
10.1161/CIRCULATIONAHA.117.029190
P407
P577
2017-05-18T00:00:00Z